Cyproterone (Acetate)
Cyproterone (Acetate) Information

About Cyproterone (Acetate)

Cyproterone (Acetate) is a hormone. Cyproterone (Acetate) is used in the treatment of prostate cancer, sexual disorders in male, hirsutism in women and acne etc.

Indications

Cyproterone (Acetate) is primarily indicated in conditions like Androgenic acne, Androgenic alopecia, Flare with initial gonadorelin therapy, Hirsutism, Idiopathic precocious puberty, Inoperable prostatic carcinoma, Male hypersexuality, Male-female transsexualism, Prostate cancer (metastatic), flare with initial gonadorelin therapy, Prostate cancer (metastatic), hot flushes with gonadorelin therapy, Prostate cancer (metastatic), long-term palliative therapy, Prostate cancer, flare with initial gonadorelin therapy, Prostate cancer, hot flushes with gonadorelin therapy, Prostate cancer, long-term palliative therapy, Prostatic cancer.

Contraindication

Cyproterone (Acetate) is contraindicated in conditions like Sickle cell anaemia,Liver diseases,Thromboembolism,Chronic depression.

Side Effects

The severe or irreversible adverse effects of Cyproterone (Acetate), which give rise to further complications include Azoospermia, Oligozoospermia.Cyproterone (Acetate) produces potentially life-threatening effects which include Jaundice, Hepatic failure. which are responsible for the discontinuation of Cyproterone (Acetate) therapy.The symptomatic adverse reactions produced by Cyproterone (Acetate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Weakness, Fatigue, Gynecomastia, Decreased libido, Decreased LH, Decreased FSH, Increased prolactin, Negative nitrogen balance, Increased plasma triglycerides, Fall in fasting plasma glucose, Decreased LDL concentrations.

Warnings

Avoid cyproterone in patients with liver disease or malignant or wasting disease, chronic depression, severe diabetes with vascular disease, sickle cell anemia or those with history of thrombo-embolic disorders. It should not be given to immature youths. In men treated with cyproterone, liver function should be monitored before treatment, if any sign or symptoms of hepatotoxicity occur then the treatment should be with drawn. In men with prostate cancer, it may be advisable to limit the duration of treatment. It should be used with caution during pregnancy.

High Risk Groups

Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.